April 2007
Worldwide Biotech;Apr2007, Vol. 19 Issue 4, p5
Trade Publication
The article provides information on the global Phase III clinical trial study by Merck KGaA aimed at assessing the efficacy and safety of Stivumax vaccine as a potential treatment for patients with unresectable stage III non-small cell lung cancer. Enrollment in the study is already open to patients in the U.S. where the first randomization has occurred. The study will evaluate patients who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy.


Related Articles

  • Biomira and Merck boosted by lung cancer vaccine.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p5 

    Reports that the stock of Biomira Inc. has more than doubled in value after the Canadian biotechnology firm released study data indicating the potential of a lung cancer vaccine developed in collaboration with Merck KGaA, Germany's fourth-largest drugmaker. Median survival for patients using the...

  • New Trial a Show of Confidence for Vaccine.  // Bioworld Week;12/14/2009, Vol. 17 Issue 50, p5 

    The article reports on the start of Phase III clinical trial of the cancer vaccine Stimuvax from the pharmaceutical company Oncothyreon Inc. by drug developer Merck KGaA in Darmstadt, Germany. Rodman and Renshaw analyst Simos Simeonidis has hypothesized that the additional investment by Merck...

  • Biomira/Merck's Liposomal shows efficacy in lung cancer treatment.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p18 

    Reports that Biomira Inc. and Merck KGaA have released results from a phase IIb clinical trial indicating that the L-BLP25 liposomal vaccine is effective in patients with stage IIIb and IV non-small cell lung cancer. Median survival of patients who were on the vaccine; Mechanism of action of the...

  • American Society of Clinical Oncology.  // BioWorld International;6/3/2009, Vol. 14 Issue 22, p5 

    The article focuses on the results of a trial for Stimulax liposomal cancer vaccine presented by Oncothyreon Inc. and partner Merck KGaA at the annual meeting of the American Society of Clinical Oncology (ASCO) in the U.S. in May 2009. Researchers found that the vaccine was well tolerated by...

  • Biomira presents positive phase II colorectal cancer trial results for Theratope vaccine.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p16 

    Reports that Biomira and collaborator Merck KGaA have released phase II data showing that patients receiving Biomira's Theratope metastatic colorectal cancer vaccine were capable of mounting an immune response to the disease while receiving concurrent chemotherapy. Results of a preliminary...

  • Biomira lung cancer vaccine receives FDA fast track status.  // PharmaWatch: Cancer;November 2004, Vol. 3 Issue 11, p5 

    Reports on Biomira's receipt of the U.S. Food and Drug Administration's granting of fast track status for its investigational lung cancer vaccine, BLP25 liposome vaccine, which is being developed with Germany's Merck KGaA. Design of the vaccine to induce an immune response to cancer cells by...

  • Biomira and Merck KGaA lung cancer vaccine increases survival time.  // PharmaWatch: Biotechnology;December2004, Vol. 3 Issue 12, p9 

    Reports Biomira Inc. and Merck KGaA have reported that data from their phase IIb Liposome vaccine trial in lung cancer patients showed that patients treated with the novel vaccine survived longer than those receiving only standard therapy. Presentation of the trial data at the 29th meeting of...

  • New Trial a Show of Confidence for Oncothyreon Cancer Vaccine. Hollingsworth, Catherine // BioWorld Today;12/11/2009, Vol. 20 Issue 238, p1 

    This article reports that Merck KGaA has started another Phase III trial of Oncothyreon Inc.'s Stimuvax cancer vaccine in patients with non-small cell lung cancer (NSCLC), marking the third Phase III trial of the liposomal vaccine. The recently initiated trial is being conducted in Asian...

  • Oncothyreon's Cancer Vaccine Stimuvax Starts Second Phase III. Morrison, Trista // BioWorld Today;6/23/2009, Vol. 20 Issue 119, p1 

    The article reports that a second Phase III trial using Stimuvax, a cancer vaccine from Oncothyreon Inc., is being conducted by Merck KGaA. The vaccine will be tested against breast cancer, which, according to Oncothyreon President and Chief Executive Officer (CEO) Robert Kirkman, has not been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics